This press release was posted on 8/5/2020 by Businesswire for Foundation Medicine:

TargetCancer - Foundation logos

TRACK Research Study Designed to Provide Genomically-Informed Treatment Recommendations to Patients while Advancing Genomic Characterization of Rare Cancers. Foundation Medicine to Provide Genomic Analyses of Tumor and Blood Samples.

CAMBRIDGE, Mass. – (BUSINESS WIRE) — TargetCancer Foundation (TCF) proudly announced today the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study, an innovative trial that brings advances in precision medicine to people living with rare cancers and their treating physicians, right in their own communities. TRACK aims to provide the treatment care team with individualized treatment recommendations, informed by genomic analysis and in consultation with field-leading rare cancer clinicians and researchers. TRACK challenges the traditional paradigm of clinical trial participation by incorporating remote consent, enabling patients to access genomic information and tailored treatment recommendations without the typical requirement to travel to an academic medical center.
Read the complete press release…

LRG Staff
Author: LRG Staff